These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 25529104)
21. A risk-benefit assessment of anti-obesity drugs. Kolanowski J Drug Saf; 1999 Feb; 20(2):119-31. PubMed ID: 10082070 [TBL] [Abstract][Full Text] [Related]
22. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity. Taylor JR; Dietrich E; Powell JG Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274 [TBL] [Abstract][Full Text] [Related]
23. Drug treatment of obesity in cardiovascular disease. Charakida M; Finer N Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446 [TBL] [Abstract][Full Text] [Related]
24. Combining behavioral and pharmacological treatments for obesity. Phelan S; Wadden TA Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334 [TBL] [Abstract][Full Text] [Related]
25. Interface between pharmacotherapy and genes in human obesity. O'Connor A; Swick AG Hum Hered; 2013; 75(2-4):116-26. PubMed ID: 24081227 [TBL] [Abstract][Full Text] [Related]
26. Medicinal strategies in the treatment of obesity. Bray GA; Tartaglia LA Nature; 2000 Apr; 404(6778):672-7. PubMed ID: 10766254 [TBL] [Abstract][Full Text] [Related]
27. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Verpeut JL; Bello NT Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397 [TBL] [Abstract][Full Text] [Related]
28. The role of orlistat in weight management. Marks S Aust Fam Physician; 2001 Apr; 30(4):335-8. PubMed ID: 11355219 [TBL] [Abstract][Full Text] [Related]
29. Pharmacologic therapy for obesity. Udall JN; Licciardi DM; Svec F J La State Med Soc; 2005 Jan; 157 Spec No 1():S56-64. PubMed ID: 15751911 [TBL] [Abstract][Full Text] [Related]
31. Why do we need drugs to treat the patient with obesity? Bray GA Obesity (Silver Spring); 2013 May; 21(5):893-9. PubMed ID: 23520198 [TBL] [Abstract][Full Text] [Related]
32. Pharmacologic agents for the treatment of obesity. Mathys M Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086 [TBL] [Abstract][Full Text] [Related]
33. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting. Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553 [TBL] [Abstract][Full Text] [Related]
34. New medications for obesity management: changing the landscape of obesity treatment. Boulghassoul-Pietrzykowska N; Franceschelli J; Still C Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):407-11. PubMed ID: 23974768 [TBL] [Abstract][Full Text] [Related]
35. Recent concepts of pharmacotherapy and bariatric surgery for childhood obesity: an overview. Gogakos A; Tzotzas TC; Krassas GE Pediatr Endocrinol Rev; 2009 Dec; 7(2):3-14. PubMed ID: 20118889 [TBL] [Abstract][Full Text] [Related]
36. Dental considerations for patients taking weight-loss medications. Donaldson M; Goodchild JH; Ziegler J J Am Dent Assoc; 2014 Jan; 145(1):70-4. PubMed ID: 24379332 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological approaches to intervention. Guy-Grand B Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S22-4. PubMed ID: 9130037 [TBL] [Abstract][Full Text] [Related]
38. Medications for weight reduction. Bray GA Endocrinol Metab Clin North Am; 2008 Dec; 37(4):923-42. PubMed ID: 19026940 [TBL] [Abstract][Full Text] [Related]